Xencor, Inc Debt Securities, Available-for-sale, Amortized Cost
Xencor, Inc (XNCR) had Debt Securities, Available-for-sale, Amortized Cost of $442.55 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $442.55M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $527.56M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $555.17M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $604.48M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $442.55M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $527.56M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $555.17M 10-K · filed 2026-02-25 |
| 2025-09-30 | $604.48M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $619.12M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $653.47M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $666.46M 10-K · filed 2025-02-27 |
| 2024-09-30 | $723.50M 10-Q/A · filed 2025-02-24 |
| 2024-06-30 | $554.88M 10-Q/A · filed 2025-02-24 |
| 2024-03-31 | $615.47M 10-Q/A · filed 2025-02-24 |
| 2023-12-31 | $641.93M 10-K/A · filed 2025-02-24 |
| 2023-09-30 | $433.94M 10-Q · filed 2023-11-08 |
| 2023-03-31 | $479.54M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $537.46M 10-K · filed 2023-02-27 |
| 2022-09-30 | $566.98M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $584.97M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $524.20M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $455.73M 10-K · filed 2022-02-24 |
| 2021-09-30 | $476.23M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $442.60M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $393.85M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $435.10M 10-K · filed 2021-02-24 |
| 2020-09-30 | $518.88M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $473.77M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $535.01M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $549.83M 10-K · filed 2020-02-25 |
| 2019-09-30 | $567.84M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $591.94M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $490.62M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $505.18M 10-K · filed 2019-02-26 |
| 2018-09-30 | $515.16M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $522.09M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $333.12M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $348.60M 10-K · filed 2018-02-28 |
| 2017-09-30 | $360.46M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $368.74M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $380.28M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $390.38M 10-Q · filed 2017-11-08 |
| 2016-09-30 | $287.33M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $160.65M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $170.46M 10-Q · filed 2016-05-02 |
| 2015-12-31 | $181.25M 10-Q · filed 2016-11-02 |
| 2015-09-30 | $139.84M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $148.09M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $47.85M 10-Q · filed 2015-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |